Investigation of the Mechanisms of Tramadol-Induced Seizures in Overdose in the Rat.

GABA overdose positron emission tomography seizure tramadol

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
12 Oct 2022
Historique:
received: 11 08 2022
revised: 09 10 2022
accepted: 10 10 2022
entrez: 27 10 2022
pubmed: 28 10 2022
medline: 28 10 2022
Statut: epublish

Résumé

Tramadol overdose is frequently associated with the onset of seizures, usually considered as serotonin syndrome manifestations. Recently, the serotoninergic mechanism of tramadol-attributed seizures has been questioned. This study’s aim was to identify the mechanisms involved in tramadol-induced seizures in overdose in rats. The investigations included (1) the effects of specific pretreatments on tramadol-induced seizure onset and brain monoamine concentrations, (2) the interaction between tramadol and γ-aminobutyric acid (GABA)A receptors in vivo in the brain using positron emission tomography (PET) imaging and 11C-flumazenil. Diazepam abolished tramadol-induced seizures, in contrast to naloxone, cyproheptadine and fexofenadine pretreatments. Despite seizure abolishment, diazepam significantly enhanced tramadol-induced increase in the brain serotonin (p < 0.01), histamine (p < 0.01), dopamine (p < 0.05) and norepinephrine (p < 0.05). No displacement of 11C-flumazenil brain kinetics was observed following tramadol administration in contrast to diazepam, suggesting that the observed interaction was not related to a competitive mechanism between tramadol and flumazenil at the benzodiazepine-binding site. Our findings do not support the involvement of serotoninergic, histaminergic, dopaminergic, norepinephrine or opioidergic pathways in tramadol-induced seizures in overdose, but they strongly suggest a tramadol-induced allosteric change of the benzodiazepine-binding site of GABAA receptors. Management of tramadol-poisoned patients should take into account that tramadol-induced seizures are mainly related to a GABAergic pathway.

Identifiants

pubmed: 36297366
pii: ph15101254
doi: 10.3390/ph15101254
pmc: PMC9607071
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Brain Res Bull. 2018 Sep;142:263-269
pubmed: 30098387
J Med Toxicol. 2011 Sep;7(3):183-8
pubmed: 21735309
Curr Neuropharmacol. 2022 Mar 27;:
pubmed: 35339181
Clin Toxicol (Phila). 2006;44(2):143-6
pubmed: 16615669
Clin Toxicol (Phila). 2019 Aug;57(8):692-696
pubmed: 30676832
Basic Clin Pharmacol Toxicol. 2008 Sep;103(3):262-6
pubmed: 18684224
Drug Chem Toxicol. 2021 Nov;44(6):613-619
pubmed: 31368376
PLoS Med. 2012;9(5):e1001213
pubmed: 22589703
Clin Chim Acta. 1993 Nov 30;221(1-2):143-58
pubmed: 7512001
Epilepsia. 2009 Jan;50(1):88-98
pubmed: 18727682
Anesth Analg. 2007 Apr;104(4):836-9
pubmed: 17377090
Anesthesiology. 2016 Jul;125(1):147-58
pubmed: 27111534
N Engl J Med. 2005 Mar 17;352(11):1112-20
pubmed: 15784664
Ann Pharmacother. 2015 Dec;49(12):1311-6
pubmed: 26369569
Acta Anaesthesiol Scand. 1998 Aug;42(7):858-63
pubmed: 9698965
Prog Neurobiol. 1997 Jun;52(2):145-57
pubmed: 9185237
J Med Toxicol. 2009 Jun;5(2):63-7
pubmed: 19415589
Clin Toxicol (Phila). 2010 May;48(4):337-41
pubmed: 20367390
J Pharmacol Exp Ther. 1975 Mar;192(3):538-41
pubmed: 1120955
Adv Pharmacol. 2017;79:1-34
pubmed: 28528665
Masui. 1992 Apr;41(4):522-31
pubmed: 1578609
Ann Emerg Med. 1989 May;18(5):542-6
pubmed: 2719365
Adv Pharm Bull. 2015 Jun;5(2):217-22
pubmed: 26236660
Ann Pharmacother. 2005 Jun;39(6):1039-44
pubmed: 15870139
Int J Prev Med. 2014 Mar;5(3):302-7
pubmed: 24829714
EJNMMI Res. 2017 Dec;7(1):17
pubmed: 28229437
J Neurosci Methods. 2006 Sep 15;155(2):272-84
pubmed: 16519945
Basic Clin Pharmacol Toxicol. 2012 Aug;111(2):133-6
pubmed: 22364547
Anesth Analg. 2007 Dec;105(6):1729-35, table of contents
pubmed: 18042875
Eur J Neurosci. 2003 Jun;17(12):2593-601
pubmed: 12823466
J Neurosci. 2005 Aug 24;25(34):7724-33
pubmed: 16120773
Anesthesiology. 2004 Nov;101(5):1128-35
pubmed: 15505448
Anesth Analg. 2005 May;100(5):1400-1405
pubmed: 15845694
Int J Toxicol. 2018 Mar/Apr;37(2):164-170
pubmed: 29554822
Pharmacol Biochem Behav. 2005 Sep;82(1):74-81
pubmed: 16140368
J Nucl Med. 2012 Dec;53(12):1974-83
pubmed: 23143088
N Engl J Med. 2015 Jan 15;372(3):241-8
pubmed: 25587948
Epilepsia. 2010 Mar;51(3):344-53
pubmed: 19674055
Naunyn Schmiedebergs Arch Pharmacol. 2010 Jan;381(1):11-9
pubmed: 20012267
Anesthesiology. 1991 Jan;74(1):97-104
pubmed: 1846065
Neuropharmacology. 2018 Jul 1;136(Pt A):10-22
pubmed: 29407219
Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):269-79
pubmed: 4110396
Anesth Analg. 1996 Sep;83(3):570-3
pubmed: 8780283
Nucl Med Biol. 2017 Jun;49:50-56
pubmed: 28364664
Circ Shock. 1992 Nov;38(3):195-201
pubmed: 1292883
J Pharmacol Exp Ther. 1992 Jan;260(1):275-85
pubmed: 1309873
Clin Pharmacokinet. 2004;43(13):879-923
pubmed: 15509185
J Neurosci. 2008 Mar 5;28(10):2527-38
pubmed: 18322097
Clin Toxicol (Phila). 2015 Jul;53(6):545-50
pubmed: 25901965
Agents Actions. 1985 Apr;16(3-4):71-5
pubmed: 4013916
Eur J Pharmacol. 2008 Jul 7;588(2-3):198-206
pubmed: 18499101
Pharmacol Biochem Behav. 1994 Mar;47(3):503-7
pubmed: 7911577
Eur J Pharmacol. 1996 Dec 27;318(1):185-92
pubmed: 9007531
Neuropsychopharmacology. 2006 Apr;31(4):730-8
pubmed: 16052243
J Nucl Med. 2016 Feb;57(2):309-14
pubmed: 26585058
Brain Res. 2003 Nov 21;991(1-2):258-61
pubmed: 14575901
Biomed Pharmacother. 2021 Jan;133:111031
pubmed: 33249277
Korean J Physiol Pharmacol. 2010 Jun;14(3):191-8
pubmed: 20631893
Crit Rev Toxicol. 2019 Sep;49(8):710-723
pubmed: 31914355
Toxicol Appl Pharmacol. 2016 Nov 1;310:108-119
pubmed: 27641627
Hum Exp Toxicol. 2008 Mar;27(3):201-5
pubmed: 18650251
Pharmacol Biochem Behav. 1979 Aug;11(2):221-6
pubmed: 41264
Epilepsy Behav. 2014 Jul;36:90-6
pubmed: 24892755
Neuroscience. 2007 Mar 30;145(3):824-31
pubmed: 17289274
Brain Res. 2000 Dec 22;887(1):183-6
pubmed: 11134603
J Nucl Med. 2009 Mar;50(3):401-8
pubmed: 19223424
Toxicology. 2012 Dec 16;302(2-3):248-54
pubmed: 22951378
Int J Rad Appl Instrum A. 1992 Nov;43(11):1383-5
pubmed: 1333459
Anesthesiology. 2015 Jan;122(1):178-89
pubmed: 25208083
J Pharmacol Exp Ther. 2008 May;325(2):500-6
pubmed: 18292293
Basic Clin Pharmacol Toxicol. 2008 Sep;103(3):228-39
pubmed: 18684226
Ann Neurol. 2016 Dec;80(6):896-908
pubmed: 27761920

Auteurs

Camille Lagard (C)

Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, F-75006 Paris, France.

Dominique Vodovar (D)

Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, F-75006 Paris, France.
Department of Medical and Toxicological Critical Care, AP-HP, Lariboisière Hospital, 75010 Paris, France.
Imagerie Moléculaire In Vivo, IMIV, CEA, INSERM, CNRS, Universités Paris-Sud et Paris-Saclay, 91471 Orsay, France.

Lucie Chevillard (L)

Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, F-75006 Paris, France.

Jacques Callebert (J)

Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, F-75006 Paris, France.
Laboratory of Biochemistry and Molecular Biology, AP-HP, Lariboisière Hospital, 75010 Paris, France.

Fabien Caillé (F)

Imagerie Moléculaire In Vivo, IMIV, CEA, INSERM, CNRS, Universités Paris-Sud et Paris-Saclay, 91471 Orsay, France.

Géraldine Pottier (G)

Imagerie Moléculaire In Vivo, IMIV, CEA, INSERM, CNRS, Universités Paris-Sud et Paris-Saclay, 91471 Orsay, France.

Hao Liang (H)

Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, F-75006 Paris, France.

Patricia Risède (P)

Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, F-75006 Paris, France.

Nicolas Tournier (N)

Imagerie Moléculaire In Vivo, IMIV, CEA, INSERM, CNRS, Universités Paris-Sud et Paris-Saclay, 91471 Orsay, France.

Bruno Mégarbane (B)

Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, F-75006 Paris, France.
Department of Medical and Toxicological Critical Care, AP-HP, Lariboisière Hospital, 75010 Paris, France.

Classifications MeSH